4 citations
,
February 2018 in “World journal of surgical oncology” This case report describes a rare instance of renal cell carcinoma metastasizing to the ovary and early onset of alopecia after beginning sunitinib treatment, though hypothyroidism and dandruff complicate attribution to the drug.
January 2018 in “Journal of the advanced practitioner in oncology” This case study provides an exemplar of a 75-year-old man with metastatic renal cell carcinoma, outlining his medical history, recent imaging findings, and treatment decisions; it reports no clinical results.
February 2012 in “Reactions Weekly” A woman got male pattern baldness from touching her husband's testosterone gel.
March 2009 in “European Urology Supplements” 508 citations
,
June 2009 in “Current drug metabolism” This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.
73 citations
,
October 2003 in “Journal of Pharmacology and Experimental Therapeutics” This study found that hair depigmentation in mice and humans can be a dynamic indicator of KIT inhibition by the drug SU11248, correlating with treatment periods.
42 citations
,
April 2012 in “Seminars in Oncology” This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” This review discusses the adverse effects on hair associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for comprehensive documentation of these effects.
February 2026 in “Pharmaceuticals” This study introduced the KRDQN predictive framework, which outperformed existing methods in predicting adverse drug reactions and provided interpretable insights into drug mechanisms, aiding pharmacovigilance and clinical decision-making.
This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.
January 2008 in “Projeto: revista mensal de arquitetura” This article reviews the cutaneous reactions associated with targeted cancer therapies and highlights the importance of dermatologists recognizing these reactions to provide effective care but reports no clinical results.
54 citations
,
September 2012 in “Acta ophthalmologica” This review highlights that various targeted cancer therapies are associated with specific ocular side-effects, emphasizing the importance of awareness among ophthalmologists for timely diagnosis and management.
22 citations
,
May 2011 in “European Journal of Cancer” This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.
46 citations
,
February 2012 in “Oncology Reports” This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.
234 citations
,
September 2004 in “Clinical cancer research” In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
11 citations
,
December 2013 in “Clinical and Experimental Dermatology” This article reviews the use of sorafenib, a multikinase inhibitor, for treating certain carcinomas, noting that cutaneous toxicity during treatment may indicate successful antitumor activity; however, it reports no new clinical results.
January 1975 in “NJEA Review” This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.
39 citations
,
June 2019 in “Frontiers in Endocrinology” This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.
June 2024 in “ESMO Gastrointestinal Oncology” The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.
December 2022 in “International Journal of Molecular Sciences” This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.
65 citations
,
February 2011 in “Molecular cancer therapeutics” This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.
1 citations
,
December 2025 in “PLoS ONE” This study evaluated the real-world safety of Tepotinib for treating NSCLC with METex14 skipping mutations, confirming known adverse events and identifying new signals like deafness and taste disorder, especially highlighting early monitoring.
215 citations
,
March 2011 in “Clinical Cancer Research” This study found that sorafenib was active against desmoid tumors, with 25% of patients achieving a partial response and 70% maintaining stable disease.
505 citations
,
October 2011 in “Journal of clinical oncology” This phase I study found that MK-2206 was well tolerated and demonstrated evidence of AKT signaling blockade in patients with advanced solid tumors, with the maximum-tolerated dose established at 60 mg.
192 citations
,
January 2015 in “Journal of the American Academy of Dermatology” This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.
28 citations
,
December 2006 in “Clinical lung cancer” This review outlines various non-rash skin toxicities associated with novel targeted anticancer therapies and provides guidelines for their early diagnosis and management, but reports no new clinical results.
4 citations
,
November 2017 in “The Journal of Dermatology” Sorafenib may cause hair loss in a way similar to alopecia areata.
4 citations
,
January 2016 in “Dermatology online journal” This report describes a case of acquired yellow hair discoloration in a 77-year-old woman, potentially caused by applying selenium sulfide after bacitracin zinc to her scalp.